<?xml version="1.0" encoding="UTF-8"?>
<ref id="B41-pharmaceuticals-10-00084" class="ref">
 <label class="label">41.</label>
 <element-citation publication-type="journal" class="element-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Bloniecki</surname>
    <given-names class="given-names">V.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Aarsland</surname>
    <given-names class="given-names">D.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Blennow</surname>
    <given-names class="given-names">K.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Cummings</surname>
    <given-names class="given-names">J.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Falahati</surname>
    <given-names class="given-names">F.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Winblad</surname>
    <given-names class="given-names">B.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Freund-Levi</surname>
    <given-names class="given-names">Y.</given-names>
   </name>
  </person-group>
  <article-title class="article-title">Effects of Risperidone and Galantamine Treatment on Alzheimerâ€™s Disease Biomarker Levels in Cerebrospinal Fluid</article-title>
  <source class="source">J. Alzheimer's Dis.</source>
  <year class="year">2017</year>
  <volume class="volume">57</volume>
  <fpage class="fpage">387</fpage>
  <lpage class="lpage">393</lpage>
  <pub-id pub-id-type="doi" class="pub-id">10.3233/JAD-160758</pub-id>
  <?supplied-pmid 28269767?>
  <pub-id pub-id-type="pmid" class="pub-id">28269767</pub-id>
 </element-citation>
</ref>
